Also known as: Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-3-[(4-methylphenyl)methylene]-, Eusolex 6300, Neo Heliopan MBC, 3-(p-Methylbenzylidene)camphor, 3-(p-Methylbenzylidene)-DL-camphor (+13 more)
INCI: ENZACAMENE
Enzacamene (4-Methylbenzylidene Camphor) (CAS 36861-47-9) is a cosmetic uv filter / sunscreen functioning as UV Filter. NOAEL 25 mg/kg bw/day (PDF-verified against ToxValDB ECHA IUCLID); EU Regulation 1223/2009 status: permitted; 4 safety opinions reviewed (sccs). Industrial safety data is also available in the chemical safety database. Same-CAS public records also appear in pharmaceutical data.
View industrial chemical safety profile for CAS 36861-47-9 →
For full compliance data across multiple jurisdictions, use the Substance Compliance tool.
Margin of Safety, dermal absorption, and sensitization profile summaries for Enzacamene (4-Methylbenzylidene Camphor).
Calculate MoS for your specific formulation with the MoS Calculator.
10 study endpoints found for Enzacamene (4-Methylbenzylidene Camphor). NOAEL (No Observed Adverse Effect Level) values are used to calculate the Margin of Safety per SCCS methodology.
| Endpoint | Value | Route | Species | Study Type | Source |
|---|---|---|---|---|---|
| NOAEL | =10 mg/kg bw/day | - | - | developmental toxicity | SCCS_vision_codex |
| NOAEL | =10 mg/kg bw/day | - | - | developmental toxicity | SCCS_vision_codex |
| NOAEL | =10 mg/kg bw/day | - | - | developmental toxicity | SCCS_vision_codex |
| NOAEL | =10 mg/kg bw/day | - | - | developmental toxicity | SCCS_vision_codex |
| NOAEL | =25 mg/kg/day | oral | rat | genotoxicity | SCCS_vision_codex |
| NOAEL | =25 mg/kg bw/day | dermal | - | repeated dose toxicity | SCCS_vision_codex |
| NOAEL | =25 mg/kg | dermal | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =25 mg/kg bw/day | oral | rat | repeated dose toxicity | SCCS_vision_codex |
| NOAEL | =25 mg/kg/day | oral | rat | genotoxicity | SCCS_vision_codex |
| NOAEL | =25 mg/kg bw/day | dermal | - | repeated dose toxicity | SCCS_vision_codex |
Official safety assessments from the Scientific Committee on Consumer Safety (SCCS) and Cosmetic Ingredient Review (CIR).
from 4 to 1 as proposed in the previous Opinion. The SCCS considers the use of a safety factor of 1 is appropriate for interspecies differences in toxicokinetics, whereas in the absence of substance specific data, a safety factor of 2.5 to account for interspecies differences in tox
from 4 to 1 as proposed in the previous Opinion. The SCCS considers the use of a safety factor of 1 is appropriate for interspecies differences in toxicokinetics, whereas in the absence of substance specific data, a safety factor of 2.5 to account for interspecies differences in tox
from 4 to 1 as proposed in the previous Opinion. The SCCS considers the use of a safety factor of 1 is appropriate for interspecies differences in toxicokinetics, whereas in the absence of substance specific data, a safety factor of 2.5 to account for interspecies differences in tox
from 4 to 1 as proposed in the previous Opinion. The SCCS considers the use of a safety factor of 1 is appropriate for interspecies differences in toxicokinetics, whereas in the absence of substance specific data, a safety factor of 2.5 to account for interspecies differences in tox
Pre-calculated NOAEL → SED → MoS audit trail for Enzacamene (4-Methylbenzylidene Camphor) across SCCS product categories, with measured dermal absorption where available.
Cross-referenced EDC classifications, mechanism data, and dose-response evidence from EDLists, SIN List, and cosmetic-specific detail sources.
Source list: I
antagonist (ER, AR, PR)
| Endpoint | Target | Value | Direction |
|---|---|---|---|
| EC50_ER | ERα | 3.99 µM | agonist |
| estrogenic_range | ERα | 10–150 µM µM | agonist |
| Cell proliferation | ER | EC50/IC50: ~1.5-2 uM (EC50); LOEC: 0.3 uM; NOEC: 0.1 uM mixed | agonist |
| Luciferase-ERE transcription | ERa | EC50/IC50: ~0.3-1 uM; LOEC: 0.1 uM; NOEC: 0.01 uM mixed | agonist |
| AR-mediated luciferase (antagonist mode) | AR | EC50/IC50: IC50 ~1-3 uM; LOEC: 1 uM; NOEC: 0.1 uM mixed | antagonist |
| PR-mediated transcription (antagonist) | PR | EC50/IC50: IC50 ~1 uM; LOEC: 1 uM; NOEC: 0.1 uM mixed | antagonist |
Additional regulatory detail beyond the 7-jurisdiction summary: Saudi SFDA, Korea MFDS, ASEAN ACD, Japan/Korea, Brazil/India, and cross-jurisdictional restriction entries.
| Jurisdiction | Status | Max % | Product Type |
|---|---|---|---|
| CN | permitted_uv_filter | 4 | All cosmetics |
| IN | permitted_uv_filter | 4.0 | sunscreen and other cosmetic products |
| MY | banned | - | All cosmetic products prohibited |
| MY | permitted_uv_filter | 4% (current); being banned — grace to Nov 2028 | - |
| MY | banned (with grace period) | 0% after Nov 2028 | Sunscreen; all cosmetic products |
Cross-database dermal penetration: EPA Dryad physics-based, Roberts Mendeley permeation, and SCCS-aggregated measured values.
| Type | DA % | Method | Skin Model | SCCS Ref |
|---|---|---|---|---|
| measured_both | 1.9 | In vivo (human forearm); in vitro (UK update) | Human in vivo forearm; human skin in vitro (UK) | SCCP/1184/08; SAG-CS Opinion 18 (2008) |
Expert safety assessment and concern-level summary for Enzacamene (4-Methylbenzylidene Camphor).
Public NOAEL study rows linked to Enzacamene (4-Methylbenzylidene Camphor) by CAS number or substance name.
Units vary across source rows: mg/kg bw/day, mg/kg/day, mg/kg
| Absorption % | Method | Vehicle |
|---|---|---|
| 1.9 | In vivo (human forearm); in vitro (UK update) | O/W emulsion; 1 g applied to 200 cm² forearm |
Same-CAS public records found in pharmaceutical data.
Same-CAS rows from the pharmaceutical spoke database.
Enzacamene (4-Methylbenzylidene Camphor) has a safety rating of "POOR" in our database. EU status: permitted. US status: prohibited. 10 toxicological study endpoint(s) are available in our database. This ingredient has been reviewed by sccs.
Enzacamene (4-Methylbenzylidene Camphor) EU regulatory status: permitted. This is based on EU Regulation 1223/2009 and its amendments.
Enzacamene (4-Methylbenzylidene Camphor) functions as: UV Filter. It is classified as a UV Filter / Sunscreen in our database. CAS number: 36861-47-9.
The NOAEL (No Observed Adverse Effect Level) for Enzacamene (4-Methylbenzylidene Camphor) is =10 mg/kg bw/day based on a developmental toxicity study via oral route in rat. A total of 10 study endpoints are available. Source: SCCS_vision_codex.
Enzacamene (4-Methylbenzylidene Camphor) also appears in pharmaceutical data. The cross-vertical cards on this page render same-CAS public rows from the matched databases.
Check Enzacamene (4-Methylbenzylidene Camphor) compliance across multiple jurisdictions:
Scan any product label with Piro — our free ingredient scanner. Point your camera at the ingredients list and get instant safety scores for every ingredient.
Try Piro Free →Paste any INCI list into the Decoder for instant safety analysis, or calculate the Margin of Safety for Enzacamene (4-Methylbenzylidene Camphor) in your formulation.